25 XP   0   0   10

NRX Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse NRX Pharmaceuticals Inc together

PenkeI guess you are interested in NRX Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NRX Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NRX Pharmaceuticals Inc

I send you an email if I find something interesting about NRX Pharmaceuticals Inc.

Quick analysis of NRX Pharmaceuticals Inc (30 sec.)










What can you expect buying and holding a share of NRX Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
4.2%

What is your share worth?

Current worth
$-0.07
Expected worth in 1 year
$-0.32
How sure are you?
37.5%

+ What do you gain per year?

Total Gains per Share
$-0.25
Return On Investment
-47.0%

For what price can you sell your share?

Current Price per Share
$0.53
Expected price per share
$0.28 - $1.03
How sure are you?
50%

1. Valuation of NRX Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)

$0.53

Intrinsic Value Per Share

$-4.28 - $-5.01

Total Value Per Share

$-4.35 - $-5.08

2. Growth of NRX Pharmaceuticals Inc (5 min.)




Is NRX Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?-$6.2m$23.6m-$24.1m-5,080.5%

How much money is NRX Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$8.2m-$13.8m$5.5m67.1%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of NRX Pharmaceuticals Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#948 / 1031

Most Revenue
#734 / 1031

Most Profit
#555 / 1031

Most Efficient
#182 / 1031

What can you expect buying and holding a share of NRX Pharmaceuticals Inc? (5 min.)

Welcome investor! NRX Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of NRX Pharmaceuticals Inc.

What can you expect buying and holding a share of NRX Pharmaceuticals Inc?

First you should know what it really means to hold a share of NRX Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of NRX Pharmaceuticals Inc is $0.53. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of NRX Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in NRX Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $-0.07. Based on the TTM, the Book Value Change Per Share is $-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is $0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of NRX Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.07-12.4%-0.09-16.1%-0.16-30.8%-0.22-42.1%-0.19-35.1%
Usd Book Value Change Per Share-0.04-7.0%-0.06-11.7%0.024.0%-0.04-7.7%0.00-0.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.012.7%0.012.3%
Usd Total Gains Per Share-0.04-7.0%-0.06-11.7%0.024.0%-0.03-5.0%0.011.7%
Usd Price Per Share0.26-0.63-2.14-8.80-8.98-
Price to Earnings Ratio-0.99--2.03--2.92--303.13--832.64-
Price-to-Total Gains Ratio-7.05--10.91-10.35-1,307.01--3,310.78-
Price to Book Ratio-3.87--55.10-8.66-89.35-83.56-
Price-to-Total Gains Ratio-7.05--10.91-10.35-1,307.01--3,310.78-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.53
Number of shares1886
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share-0.06-0.04
Usd Total Gains Per Share-0.06-0.03
Gains per Quarter (1886 shares)-117.33-50.20
Gains per Year (1886 shares)-469.31-200.79
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-469-479108-309-211
20-939-948217-618-412
30-1408-1417325-927-613
40-1877-1886433-1236-814
50-2347-2355541-1545-1015
60-2816-2824650-1854-1216
70-3285-3293758-2163-1417
80-3754-3762866-2472-1618
90-4224-4231974-2781-1819
100-4693-47001083-3090-2020

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%4.016.00.020.0%6.018.00.025.0%6.018.00.025.0%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%6.014.00.030.0%9.015.00.037.5%9.015.00.037.5%
Dividend per Share0.00.04.00.0%1.00.011.08.3%1.00.019.05.0%1.00.023.04.2%1.00.023.04.2%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%6.014.00.030.0%9.015.00.037.5%9.015.00.037.5%

Fundamentals of NRX Pharmaceuticals Inc

About NRX Pharmaceuticals Inc

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics based on N-methyl-D-aspartate platform for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned FDA-designated investigational breakthrough therapy for suicidal treatment-resistant bipolar depression and chronic pain; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of acute suicidality in depression. The company has a partnership with Alvogen and Lotus to develop and commercialize NRX-101 for the suicidal bipolar depression treatment, as well as an agreement with Nephron Pharmaceuticals, Inc. to develop ketamine. The company was founded in 2015 and is based in Wilmington, Delaware.

Fundamental data was last updated by Penke on 2024-03-21 01:28:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NRX Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit NRX Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--171.8%+171.8%
TTM--205.8%+205.8%
YOY--262.1%+262.1%
5Y--455.6%+455.6%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient NRX Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • -46.2% Return on Assets means that NRX Pharmaceuticals Inc generated $-0.46 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NRX Pharmaceuticals Inc:

  • The MRQ is -46.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -42.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-46.2%TTM-42.6%-3.6%
TTM-42.6%YOY-42.4%-0.2%
TTM-42.6%5Y-105.2%+62.6%
5Y-105.2%10Y-87.6%-17.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-46.2%-12.5%-33.7%
TTM-42.6%-12.2%-30.4%
YOY-42.4%-11.2%-31.2%
5Y-105.2%-13.4%-91.8%
10Y-87.6%-14.7%-72.9%
1.1.3. Return on Equity

Shows how efficient NRX Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • 0.0% Return on Equity means NRX Pharmaceuticals Inc generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-19.3%+19.3%
TTM-19.3%YOY-63.6%+44.3%
TTM-19.3%5Y-38.3%+18.9%
5Y-38.3%10Y-32.0%-6.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--15.8%+15.8%
TTM-19.3%-15.7%-3.6%
YOY-63.6%-13.9%-49.7%
5Y-38.3%-18.3%-20.0%
10Y-32.0%-19.2%-12.8%

1.2. Operating Efficiency of NRX Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient NRX Pharmaceuticals Inc is operating .

  • Measures how much profit NRX Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.1%+299.1%
TTM--210.1%+210.1%
YOY--279.7%+279.7%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient NRX Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.861-2.861
TTM-3.193-3.193
YOY-3.615-3.615
5Y-5.560-5.560
10Y-7.396-7.396

1.3. Liquidity of NRX Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if NRX Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.68 means the company has $0.68 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.677. The company is unable to pay all its short-term debts. -2
  • The TTM is 1.048. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ0.677TTM1.048-0.371
TTM1.048YOY3.516-2.468
TTM1.0485Y1.065-0.017
5Y1.06510Y1.397-0.332
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6773.986-3.309
TTM1.0484.440-3.392
YOY3.5165.552-2.036
5Y1.0656.158-5.093
10Y1.3976.492-5.095
1.3.2. Quick Ratio

Measures if NRX Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.46 means the company can pay off $0.46 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.461. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.790. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.461TTM0.790-0.329
TTM0.790YOY2.893-2.103
TTM0.7905Y27.070-26.280
5Y27.07010Y105,932.562-105,905.492
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4613.638-3.177
TTM0.7904.168-3.378
YOY2.8935.515-2.622
5Y27.0706.012+21.058
10Y105,932.5626.209+105,926.353

1.4. Solvency of NRX Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of NRX Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare NRX Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 1.47 means that NRX Pharmaceuticals Inc assets are financed with 147.4% credit (debt) and the remaining percentage (100% - 147.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 1.474. The company is unable to pay all its debts by selling its assets. -2
  • The TTM is 1.086. The company is just not able to pay all its debts by selling its assets. -1
Trends
Current periodCompared to+/- 
MRQ1.474TTM1.086+0.389
TTM1.086YOY0.295+0.791
TTM1.0865Y1.316-0.230
5Y1.31610Y1.135+0.180
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4740.335+1.139
TTM1.0860.330+0.756
YOY0.2950.267+0.028
5Y1.3160.367+0.949
10Y1.1350.378+0.757
1.4.2. Debt to Equity Ratio

Measures if NRX Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.0% means that company has $0.00 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NRX Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM0.621-0.621
TTM0.621YOY0.427+0.194
TTM0.6215Y0.631-0.010
5Y0.63110Y1.064-0.433
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.376-0.376
TTM0.6210.398+0.223
YOY0.4270.334+0.093
5Y0.6310.429+0.202
10Y1.0640.476+0.588

2. Market Valuation of NRX Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings NRX Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare NRX Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -0.99 means the investor is paying $-0.99 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NRX Pharmaceuticals Inc:

  • The EOD is -2.020. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.991. Based on the earnings, the company is expensive. -2
  • The TTM is -2.034. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.020MRQ-0.991-1.029
MRQ-0.991TTM-2.034+1.043
TTM-2.034YOY-2.916+0.882
TTM-2.0345Y-303.134+301.100
5Y-303.13410Y-832.645+529.511
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.020-2.643+0.623
MRQ-0.991-2.418+1.427
TTM-2.034-2.742+0.708
YOY-2.916-4.123+1.207
5Y-303.134-6.257-296.877
10Y-832.645-6.478-826.167
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NRX Pharmaceuticals Inc:

  • The EOD is -2.682. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.316. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.083. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-2.682MRQ-1.316-1.366
MRQ-1.316TTM-2.083+0.767
TTM-2.083YOY-4.727+2.644
TTM-2.0835Y-931.108+929.026
5Y-931.10810Y-1,104.921+173.813
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-2.682-3.244+0.562
MRQ-1.316-2.939+1.623
TTM-2.083-3.478+1.395
YOY-4.727-5.592+0.865
5Y-931.108-8.473-922.635
10Y-1,104.921-8.881-1,096.040
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of NRX Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of -3.87 means the investor is paying $-3.87 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NRX Pharmaceuticals Inc:

  • The EOD is -7.879. Based on the equity, the company is expensive. -2
  • The MRQ is -3.865. Based on the equity, the company is expensive. -2
  • The TTM is -55.104. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.879MRQ-3.865-4.014
MRQ-3.865TTM-55.104+51.239
TTM-55.104YOY8.661-63.765
TTM-55.1045Y89.350-144.454
5Y89.35010Y83.562+5.788
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.8792.124-10.003
MRQ-3.8652.041-5.906
TTM-55.1042.118-57.222
YOY8.6612.915+5.746
5Y89.3503.682+85.668
10Y83.5624.114+79.448
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of NRX Pharmaceuticals Inc.

3.1. Institutions holding NRX Pharmaceuticals Inc

Institutions are holding 4.494% of the shares of NRX Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc1.576401445177-5416-0.3734
2023-12-31AdvisorShares Investments, LLC0.7010.06926426326426320
2023-12-31Geode Capital Management, LLC0.4493041192200
2023-12-31BlackRock Inc0.3171029071400
2023-12-31Renaissance Technologies Corp0.21870.00012004803670022.4081
2023-12-31Royal Bank of Canada0.16380150209-20210-11.859
2023-12-31One Wealth Management Investment & Advisory Services LLC0.15320.02881404021404020
2023-12-31Bridgeway Capital Management, LLC0.13380.0012122700-38000-23.6465
2023-12-31State Street Corporation0.1246011424000
2023-12-31Northern Trust Corp0.081807499600
2023-12-31Texas Capital Bank Wealth Management Services Inc0.0690.00346329000
2023-12-31UBS Group AG0.0511046837456273770.8264
2023-12-31Morgan Stanley - Brokerage Accounts0.0484044334-2992-6.3221
2023-12-31Charles Schwab Investment Management Inc0.047704373200
2023-12-31Hbk Sorce Advisory LLC0.03190.00052923000
2023-12-31Tower Research Capital LLC0.02150.00011969610515114.53
2023-12-31Group One Trading, LP0.020901915800
2023-12-31United Asset Strategies Inc0.020.0011830000
2023-12-31JPMorgan Chase & Co0.0183016812164734859.292
2023-12-31LPL Financial Corp0.0159014568221017.8832
Total 4.26440.10433909429+827941+21.2%

3.2. Funds holding NRX Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Vanguard Total Stock Mkt Idx Inv1.0678097892100
2024-02-29AdvisorShares Psychedelics ETF0.89964.333782466800
2024-01-31Vanguard Institutional Extnd Mkt Idx Tr0.48980.000244907100
2024-01-31Fidelity Extended Market Index0.28180.000325832900
2023-09-30Bridgeway Ultra-Small Company Market0.17530.024916070000
2024-01-31Fidelity Series Total Market Index0.0665060921803215.1865
2023-09-30BlackRock Extended Mkt Composite0.06360.00015828000
2023-12-31BlackRock Extended Equity Market K0.05550.000250844-102-0.2002
2024-01-31Fidelity Total Market Index0.048604457300
2024-01-31Schwab Total Stock Market Index0.04770.00014373200
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04160.00033818000
2023-12-31Northern Trust Extended Eq Market Idx0.04160.00033818000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03570.00023274800
2024-01-31Fidelity Nasdaq Composite Index0.03370.00013090700
2024-01-31LUX IM Global Medtech HX0.03280.00533004300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02870.000226301490.1867
2024-01-31Vanguard Instl Ttl Stk Mkt Idx InstlPls0.018701718500
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.0187017185-961736-98.2445
2024-01-31Spartan Total Market Index Pool E0.016901551000
2024-01-31Spartan Extended Market Index Pool E0.01020.0002933200
Total 3.47484.36613185610-953757-29.9%

3.3. Insider Transactions

Insiders are holding 31.108% of the shares of NRX Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-08-30Aaron GorovitzBUY350000.32
2023-08-22Jonathan C JavittBUY2000000.32

4. Summary

4.1. Key Performance Indicators

The key performance indicators of NRX Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.037-0.062+69%0.021-274%-0.041+11%-0.003-92%
Book Value Per Share---0.067-0.005-92%0.256-126%0.167-140%0.236-129%
Current Ratio--0.6771.048-35%3.516-81%1.065-36%1.397-52%
Debt To Asset Ratio--1.4741.086+36%0.295+400%1.316+12%1.135+30%
Debt To Equity Ratio---0.621-100%0.427-100%0.631-100%1.064-100%
Dividend Per Share----0%-0%0.014-100%0.012-100%
Eps---0.066-0.085+30%-0.163+149%-0.223+240%-0.186+184%
Free Cash Flow Per Share---0.049-0.072+47%-0.116+134%-0.052+5%-0.044-12%
Free Cash Flow To Equity Per Share---0.066-0.025-61%-0.056-15%-0.052-22%-0.012-82%
Gross Profit Margin--1.0001.0000%113.115-99%23.517-96%19.764-95%
Intrinsic Value_10Y_max---5.008--------
Intrinsic Value_10Y_min---4.280--------
Intrinsic Value_1Y_max---0.363--------
Intrinsic Value_1Y_min---0.356--------
Intrinsic Value_3Y_max---1.196--------
Intrinsic Value_3Y_min---1.140--------
Intrinsic Value_5Y_max---2.157--------
Intrinsic Value_5Y_min---1.993--------
Market Cap48985568.000+51%24030656.00058066383.200-59%198021848.000-88%813497782.240-97%829723866.533-97%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio-7.879-104%-3.865-55.104+1326%8.661-145%89.350-104%83.562-105%
Pe Ratio-2.020-104%-0.991-2.034+105%-2.916+194%-303.134+30488%-832.645+83918%
Price Per Share0.530+51%0.2600.628-59%2.143-88%8.802-97%8.977-97%
Price To Free Cash Flow Ratio-2.682-104%-1.316-2.083+58%-4.727+259%-931.108+70667%-1104.921+83877%
Price To Total Gains Ratio-14.369-104%-7.049-10.909+55%10.348-168%1307.011-101%-3310.778+46867%
Quick Ratio--0.4610.790-42%2.893-84%27.070-98%105932.562-100%
Return On Assets---0.462-0.426-8%-0.424-8%-1.052+127%-0.876+90%
Return On Equity----0.1930%-0.6360%-0.3830%-0.3200%
Total Gains Per Share---0.037-0.062+69%0.021-274%-0.027-28%0.009-503%
Usd Book Value---6217000.000-475000.000-92%23657250.000-126%15460850.550-140%21779011.583-129%
Usd Book Value Change Per Share---0.037-0.062+69%0.021-274%-0.041+11%-0.003-92%
Usd Book Value Per Share---0.067-0.005-92%0.256-126%0.167-140%0.236-129%
Usd Dividend Per Share----0%-0%0.014-100%0.012-100%
Usd Eps---0.066-0.085+30%-0.163+149%-0.223+240%-0.186+184%
Usd Free Cash Flow---4566000.000-6696500.000+47%-10682072.750+134%-4811842.700+5%-4032290.167-12%
Usd Free Cash Flow Per Share---0.049-0.072+47%-0.116+134%-0.052+5%-0.044-12%
Usd Free Cash Flow To Equity Per Share---0.066-0.025-61%-0.056-15%-0.052-22%-0.012-82%
Usd Market Cap48985568.000+51%24030656.00058066383.200-59%198021848.000-88%813497782.240-97%829723866.533-97%
Usd Price Per Share0.530+51%0.2600.628-59%2.143-88%8.802-97%8.977-97%
Usd Profit---6062000.000-8285750.000+37%-13843263.500+128%-8793036.700+45%-7330366.833+21%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.037-0.062+69%0.021-274%-0.027-28%0.009-503%
 EOD+6 -2MRQTTM+13 -15YOY+9 -205Y+12 -1910Y+8 -23

4.2. Fundamental Score

Let's check the fundamental score of NRX Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-2.020
Price to Book Ratio (EOD)Between0-1-7.879
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.461
Current Ratio (MRQ)Greater than10.677
Debt to Asset Ratio (MRQ)Less than11.474
Debt to Equity Ratio (MRQ)Less than10.000
Return on Equity (MRQ)Greater than0.150.000
Return on Assets (MRQ)Greater than0.05-0.462
Total1/10 (10.0%)

4.3. Technical Score

Let's check the technical score of NRX Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.999
Ma 20Greater thanMa 500.526
Ma 50Greater thanMa 1000.464
Ma 100Greater thanMa 2000.418
OpenGreater thanClose0.529
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Net Debt  -18,2498,720-9,5295,212-4,3172,040-2,2773,4441,167



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets13,110
Total Liabilities19,327
Total Stockholder Equity-6,217
 As reported
Total Liabilities 19,327
Total Stockholder Equity+ -6,217
Total Assets = 13,110

Assets

Total Assets13,110
Total Current Assets13,089
Long-term Assets21
Total Current Assets
Cash And Cash Equivalents 8,902
Net Receivables 6
Other Current Assets 4,181
Total Current Assets  (as reported)13,089
Total Current Assets  (calculated)13,089
+/-0
Long-term Assets
Long-term Assets Other 21
Long-term Assets  (as reported)21
Long-term Assets  (calculated)21
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities19,327
Long-term Liabilities0
Total Stockholder Equity-6,217
Total Current Liabilities
Short-term Debt 10,069
Short Long Term Debt 10,069
Accounts payable 3,631
Other Current Liabilities 10
Total Current Liabilities  (as reported)19,327
Total Current Liabilities  (calculated)23,779
+/- 4,452
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock84
Retained Earnings -248,815
Accumulated Other Comprehensive Income -22
Other Stockholders Equity 242,533
Total Stockholder Equity (as reported)-6,217
Total Stockholder Equity (calculated)-6,220
+/- 3
Other
Capital Stock87
Cash and Short Term Investments 8,902
Common Stock Shares Outstanding 81,947
Current Deferred Revenue5,617
Liabilities and Stockholders Equity 13,110
Net Debt 1,167
Net Invested Capital 3,849
Net Working Capital -6,238
Short Long Term Debt Total 10,069



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-30
> Total Assets 
174
69,566
69,553
69,699
69,885
70,796
71,708
50,103
41,685
32,075
6,273
6,277
6,032
6,050
2,941
18,547
45,250
32,729
43,601
32,433
24,824
25,816
21,780
19,809
13,110
13,11019,80921,78025,81624,82432,43343,60132,72945,25018,5472,9416,0506,0326,2776,27332,07541,68550,10371,70870,79669,88569,69969,55369,566174
   > Total Current Assets 
82
536
335
216
124
30
51
41
208
69
81
37
97
82
2,930
18,534
45,234
32,714
43,584
32,414
24,801
25,795
21,756
19,788
13,089
13,08919,78821,75625,79524,80132,41443,58432,71445,23418,5342,930829737816920841513012421633553682
       Cash And Cash Equivalents 
82
449
267
140
77
11
2
1
194
0
81
0
40
0
1,859
13,386
38,884
27,605
40,202
24,548
18,249
20,054
16,506
14,969
8,902
8,90214,96916,50620,05418,24924,54840,20227,60538,88413,3861,859040081019412117714026744982
       Short-term Investments 
0
69,029,443
69,029,443
0
0
70,766
71,657
50,061
41,477
32,005
6,192
6,240
5,935
0
5,968
0
0
0
0
0
0
0
0
0
0
00000000005,96805,9356,2406,19232,00541,47750,06171,65770,7660069,029,44369,029,4430
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
831
0
0
0
0
554
547
7
6
6
6
6667547554000083100000000000000
       Other Current Assets 
0
-69,029,356
68
76
47
19
49
40
14
69
0
37
57
0
26
5,148
6,351
5,109
3,382
7,866
6,552
5,741
5,250
4,819
4,181
4,1814,8195,2505,7416,5527,8663,3825,1096,3515,148260573706914404919477668-69,029,3560
   > Long-term Assets 
91
69,029
69,218
69,483
69,761
70,766
71,657
50,061
41,477
32,005
6,192
6,240
5,935
0
11
13
16
15
17
19
23
21
24
21
21
212124212319171516131105,9356,2406,19232,00541,47750,06171,65770,76669,76169,48369,21869,02991
       Long-term Assets Other 
91
0
218
483
-239
-234
-343
61
477
5
192
240
-65
0
11
13
16
15
17
19
23
21
24
21
21
21212421231917151613110-65240192547761-343-234-239483218091
> Total Liabilities 
150
64,566
65
217
376
1,257
1,981
2,108
2,434
2,574
2,497
2,651
2,831
3,937
46,712
35,984
36,283
11,923
11,912
7,081
8,042
18,407
22,064
22,617
19,327
19,32722,61722,06418,4078,0427,08111,91211,92336,28335,98446,7123,9372,8312,6512,4972,5742,4342,1081,9811,2573762176564,566150
   > Total Current Liabilities 
150
93
65
217
376
567
494
521
642
622
316
297
2,831
610
46,164
35,472
36,283
11,923
11,912
7,081
8,042
15,585
22,064
22,617
19,327
19,32722,61722,06415,5858,0427,08111,91211,92336,28335,47246,1646102,8312973166226425214945673762176593150
       Short-term Debt 
100
0
0
0
0
0
0
0
0
0
0
0
2,451
0
249
174
515
518
520
0
0
7,703
12,189
12,692
10,069
10,06912,69212,1897,7030052051851517424902,45100000000000100
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
174
515
518
520
0
0
7,703
12,189
12,692
10,069
10,06912,69212,1897,70300520518515174000000000000000
       Accounts payable 
100
86
61
204
328
551
446
432
537
622
313
0
0
0
3,153
6,268
5,559
3,687
4,311
3,078
2,168
2,076
3,776
2,205
3,631
3,6312,2053,7762,0762,1683,0784,3113,6875,5596,2683,1530003136225374324465513282046186100
       Other Current Liabilities 
-50
8
4
13
48
16
48
89
104
0
3
297
379
0
-1,200
26,390
27,059
4,874
7,081
4,003
5,874
5,806
6,099
36
10
10366,0995,8065,8744,0037,0814,87427,05926,390-1,200037929730104894816481348-50
   > Long-term Liabilities 
0
85,671
64,488
64,482
64,510
690
1,487
1,587
1,792
1,952
2,181
2,354
1,091
0
548
512
0
4,205
7,601
4,003
5,874
2,822
3,776
0
0
003,7762,8225,8744,0037,6014,205051254801,0912,3542,1811,9521,7921,5871,48769064,51064,48264,48885,6710
> Total Stockholder Equity
24
5,000
69,488
69,482
69,510
69,539
69,727
47,995
39,251
29,500
3,776
3,626
3,201
2,114
-43,771
-17,437
8,967
20,806
31,689
25,352
16,782
7,409
-284
-2,808
-6,217
-6,217-2,808-2847,40916,78225,35231,68920,8068,967-17,437-43,7712,1143,2013,6263,77629,50039,25147,99569,72769,53969,51069,48269,4885,00024
   Common Stock
2
3
64,491
64,484
64,512
64,541
64,730
42,998
34,254
24,503
3
3
3
3
43
49
55
59
67
67
68
67
70
80
84
8480706768676759554943333324,50334,25442,99864,73064,54164,51264,48464,49132
   Retained Earnings 
-1
-105
-90
-96
-68
-39
149
325
384
369
643
493
367
-720
-90,180
-131,677
-152,450
-183,243
-196,691
-203,673
-212,756
-222,997
-234,036
-242,753
-248,815
-248,815-242,753-234,036-222,997-212,756-203,673-196,691-183,243-152,450-131,677-90,180-720367493643369384325149-39-68-96-90-105-1
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
3,130
3,130
2,831
2,831
2,831
114,191
161,362
0
228,313
0
229,470
0
233,576
239,887
0
0239,887233,5760229,4700228,3130161,362114,1912,8312,8312,8313,1303,1300000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
23
5,102
5,087
5,094
5,065
5,036
4,848
4,672
4,613
4,628
3,130
3,130
2,831
0
46,366
114,191
161,362
203,990
228,313
228,958
229,470
230,339
233,576
239,887
242,533
242,533239,887233,576230,339229,470228,958228,313203,990161,362114,19146,36602,8313,1303,1304,6284,6134,6724,8485,0365,0655,0945,0875,10223



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-33,319
Operating Income-33,319-33,319
 
Operating Expense (+$)
Research Development15,293
Selling General Administrative17,776
Selling And Marketing Expenses-
Operating Expense33,31933,069
 
Net Interest Income (+$)
Interest Income550
Interest Expense-37
Other Finance Cost-0
Net Interest Income513
 
Pretax Income (+$)
Operating Income-33,319
Net Interest Income513
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-36,059-30,066
EBIT - interestExpense = -37
-36,059
-36,022
Interest Expense37
Earnings Before Interest and Taxes (EBIT)--36,022
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-36,059
Tax Provision--
Net Income From Continuing Ops-36,059-36,059
Net Income-36,059
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-3,253-513
 

Technical Analysis of NRX Pharmaceuticals Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of NRX Pharmaceuticals Inc. The general trend of NRX Pharmaceuticals Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine NRX Pharmaceuticals Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NRX Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.7333 < 1.02 < 1.03.

The bearish price targets are: 0.405 > 0.28 > 0.28.

Tweet this
NRX Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NRX Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NRX Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NRX Pharmaceuticals Inc. The current macd is 0.01531405.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the NRX Pharmaceuticals Inc price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for NRX Pharmaceuticals Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the NRX Pharmaceuticals Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
NRX Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartNRX Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NRX Pharmaceuticals Inc. The current adx is 21.34.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy NRX Pharmaceuticals Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
NRX Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NRX Pharmaceuticals Inc. The current sar is 0.48179992.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
NRX Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NRX Pharmaceuticals Inc. The current rsi is 53.00. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
NRX Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartNRX Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NRX Pharmaceuticals Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the NRX Pharmaceuticals Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NRX Pharmaceuticals Inc Daily Stochastic Oscillator ChartNRX Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NRX Pharmaceuticals Inc. The current cci is 4.0741023.

NRX Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartNRX Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NRX Pharmaceuticals Inc. The current cmo is 6.34044941.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
NRX Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartNRX Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NRX Pharmaceuticals Inc. The current willr is -60.31746032.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that NRX Pharmaceuticals Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
NRX Pharmaceuticals Inc Daily Williams %R ChartNRX Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NRX Pharmaceuticals Inc. The current atr is 0.07263744.

NRX Pharmaceuticals Inc Daily Average True Range (ATR) ChartNRX Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NRX Pharmaceuticals Inc. The current obv is 166,741,966.

NRX Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartNRX Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NRX Pharmaceuticals Inc. The current mfi is 48.18.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
NRX Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartNRX Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NRX Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-06BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-09CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-18CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-09WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-21CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-05CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-07RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

NRX Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NRX Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.999
Ma 20Greater thanMa 500.526
Ma 50Greater thanMa 1000.464
Ma 100Greater thanMa 2000.418
OpenGreater thanClose0.529
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of NRX Pharmaceuticals Inc with someone you think should read this too:
  • Are you bullish or bearish on NRX Pharmaceuticals Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about NRX Pharmaceuticals Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NRX Pharmaceuticals Inc

I send you an email if I find something interesting about NRX Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about NRX Pharmaceuticals Inc.

Receive notifications about NRX Pharmaceuticals Inc in your mailbox!